“The core message is that DLBCL can no longer be viewed as a single disease,” explained senior author Dr. Louis M. Staudt, Director of NCI’s Center for Cancer Genomics.
A highly selective small molecule A3AR agonist blocked development of oxaliplatin-induced neuropathic pain without interfering with anticancer effects.
Given disconcerting low success rates overall in immunotherapy, some leading oncologists are calling for greater scientific rigor in clinical trial design.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination.
Antibody-mediated, immunotherapeutic strategies targeting survivin, a key cancer-related protein, may offer benefit in a variety of cancers.
A USCF team has uncovered molecular insights into meningioma biology that could lead to new, less toxic treatment approaches.
A significant number of patients receiving immune checkpoint inhibitor therapy have developed myocarditis, but the reasons behind it are still unclear.
A team of Finnish researchers has created a deep learning algorithm that appears to help clinicians better predict patient outcomes based on colorectal cancer tissue samples.
A new joint review from ASCO and CAP found insufficient evidence of clinical validity and utility for the use of most ctDNA assays in advanced cancer.